Study identifies associations between childhood unilateral amblyopia and cardiometabolic disorders

News
Article

Investigators examined the connection between amblyopia, components of the metabolic syndrome and individual cardiometabolic diseases

Blood cells traveling through a blood vessel. Image credit: ©Dr_Microbe – stock.adobe.com

Investigators reviewed retinal photography and optical coherence tomography images for morphologic features of the optic nerve, the retinal vasculature and sublayers. ©Dr_Microbe – stock.adobe.com

First author Siegfried Karl Wagner, MD, FRCOphth and colleagues conducted a study to identify association between unilateral childhood amblyopia and cardiometabolic disorders in adulthood. The research findings reported greater cardiometabolic dysfunction in adults who had childhood amblyopia.1 Dr.Wagner is from the Institute of Ophthalmology, University College London, and the NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology London, both in London.

The prospective cohort study included 126,399 participants in the United Kingdom Biobank who underwent an ocular examination, of whom 67,321 underwent retinal imaging. The investigators wanted to determine if there was an association between amblyopia and components of the metabolic syndrome and individual cardiometabolic diseases. Childhood amblyopia, classified as resolved or persisting into adulthood, cardiometabolic disease and mortality were defined using ophthalmic assessment, self-reported hospital admissions and death records, they explained.

Retinal photography and optical coherence tomography images were reviewed for morphologic features of the optic nerve and the retinal vasculature and sublayers.

Analysis findings

The investigators reported that participants with persistent amblyopia (n = 2,647) were more likely to be obese, hypertensive and diabetic compared with participants who did not have amblyopia (controls, n = 18,481 controls). The presence of persistent amblyopia also was associated with an increased risk of myocardial infarction and death.

Evaluation of the amblyopic eyes on retinal images showed that the eyes had significantly increased venular caliber and increased tortuosity but lower fractal dimension and a thinner ganglion cell-inner plexiform layer. The amblyopic eyes with a persisting visual deficit had lower optic nerve disc height and width compared to the control eyes.

Evaluation of the unaffected fellow eyes of participants with amblyopia also had significantly lower retinal fractal dimension and a thinner ganglion cell-inner plexiform layer.

The authors pointed out that differences in the retinal features in the amblyopic eye and the unaffected non-amblyopic eye suggested a generalised versus local processes.

Commenting on their findings, Dr Wagner and colleagues said, “Adults who had amblyopia in childhood have increased risk of cardiovascular disease and metabolic dysfunction. Optic nerve morphology should be investigated further as a prognostic factor for treatment response in children undergoing treatment for amblyopia. As a leading cause of childhood visual impairment, amblyopia may also represent a relatively common and accessible neurodevelopmental model for research into the early life factors of health and disease.”

The authors advised that while “further longitudinal research is needed to understand the basis of the observed associations, healthcare professionals should be cognisant of greater cardiometabolic dysfunction in adults who had childhood amblyopia. Differences in retinal features in both the amblyopic eye and the unaffected non-amblyopic eye suggest a generalised disease process versus local disease processes.”

Reference

Wagner SK, Bountziouka V, Hysi P, Rahi JS, on behalf of the UK Biobank Eye & Vision Consortium. Associations between unilateral amblyopia in childhood and cardiometabolic disorders in adult life: a cross-sectional and longitudinal analysis of the UK Biobank. eClinicalMedicine 2024;70:102493

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.